These results were not L-Asarinin confirmed in the study by Siegmund et al., who found similar results in both groups after treatment. However, this study employed 11 sessions, but it can be observed that the administration of DCS produced better results in the middle of the treatment. This again suggests that the administration of DCS in brief protocols can be effective. Another possible explanation for the weak efficacy of DCS discussed in the study refers to the good response to therapy in the placebo group. The participants in the placebo group showed a reduction of symptoms of 58% at the last evaluation. This result was not found in the other studies with DCS and Diniconazole suggested a floor effect preventing additional effects with DCS. Siegmund et al. suggested that this effect may be due to the higher dose of psychotherapy: 8690 min group therapy plus three individual exposures. PTSD is the only disorder in which DCS seems to have played only a minimal role as an enhancer of CBT. The protocol used by Kleine et al. does not seem to have been effective even in midtreatment. This may be due to the specificity of PTSD, which is an anxiety disorder whose time of conditioning is necessarily known. For this reason, it may involve different brain mechanisms that respond differently to the action of DCS. In this study with PTSD, DCS enhanced outcomes in the subgroup of regular completers only, who are the participants who completed all sessions. Regarding tolerability, DCS was well tolerated with no significant adverse effects found in the reviewed studies. In Hofmann et. al., DCS administration had two spontaneous notifications of acute adverse effects: nightmare the night after administration and exposure session in one participant, and euphoric mood and increased energy in one participant with chronic depression. In Storch et al., only three participants of the DCS group reported adverse events that were considered moderate: Increased anxiety, drowsiness and dry mouth. For the placebo group, these included drowsiness and restlessness. Kushner et al. found mild gastrointestinal distress, dizziness, fatigue, and anxiety in four participants in the DCS group and ����jittery feelings����, dissociation and dry lips in three participants in the placebo group.